2020 ASCO Virtual Direct™ Highlights
2020 ASCO Follow up on Adjuvant Therapy in High-risk Melanoma: Does Pembro Provide Sustained RFS Benefit in Resected Stage III Melanoma? Is There a Long-term Survival Benefit With Dabrafenib + Trametinib in BRAF+ Disease?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Gary Doolittle
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Gary Doolittle
Comments 0
Login to view comments.
Click here to Login
